Skip to main content

Market Overview

54 Stocks Moving In Thursday's Mid-Day Session

Share:

Gainers

  • Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39.
  • Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment recently reported better-than-expected Q4 sales results.
  • ShiftPixy, Inc. (NASDAQ: PIXY) surged 22.5% to $3.075 as the company said it has been named as sponsor related to 4 SPACs.
  • JAKKS Pacific, Inc. (NASDAQ: JAKK) jumped 20% to $8.80 after the company reported better-than-expected Q1 results.
  • Galera Therapeutics, Inc. (NASDAQ: GRTX) gained 20% to $7.93 after the company announced updated results from its Phase 1/2 pilot trial of GC4419, versus placebo, in patients with locally advanced pancreatic cancer who are undergoing stereotactic body radiation therapy.
  • 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) rose 18.1% to $29.31 after the company reported better-than-expected Q3 results.
  • VEREIT, Inc. (NYSE: VER) gained 17% to $48.29 after the company announced an all-stock merger agreement with Realty Income.
  • MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) gained 16.5% to $10.43.
  • Ocular Therapeutix, Inc. (NASDAQ: OCUL) surged 15.3% to $18.00. Ocular Therapeutix, reported multiple scientific presentations at the Association for Research in Vision and Ophthalmology Annual Meeting.
  • Atossa Therapeutics, Inc. (NASDAQ: ATOS) jumped 15% to $2.53.
  • Communications Systems, Inc. (NASDAQ: JCS) gained 14.6% to $6.74 as the company agreed to sell its Transition Networks and Net2Edge businesses to Lantronix.
  • Realogy Holdings Corp. (NYSE: RLGY) surged 14% to $17.39 following upbeat quarterly results.
  • Vaxart, Inc. (NASDAQ: VXRT) gained 13% to $9.52 as the company said its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the World Vaccine Congress Washington that will be held virtually from May 4-6, 2021.
  • AtriCure, Inc. (NASDAQ: ATRC) surged 12.5% to $78.56 after the company reported that its EPi-Sense System was approved by the FDA for treatment of long-standing persistent afib patients.
  • Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares climbed 11.9% to $4.42 after the company signed exclusive worldwide license agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the company's exosome technology portfolio.
  • Extreme Networks, Inc. (NASDAQ: EXTR) surged 10.5% to $11.81. The company recently reported better-than-expected Q3 results.
  • Alliance Data Systems Corporation (NYSE: ADS) gained 10.4% to $119.07 following upbeat Q1 results.
  • Nokia Corporation (NYSE: NOK) shares climbed 10.2% to $4.63 after reporting upbeat Q1 results.
  • Bloomin' Brands, Inc. (NASDAQ: BLMN) gained 9.3% to $31.48 after the company reported better-than-expected Q1 results.
  • MRC Global Inc. (NYSE: MRC) surged 8.8% to $9.86. The company recently released Q1 results.
  • Cheesecake Factory Inc (NASDAQ: CAKE) rose 6.3% to $62.69 after reporting higher quarterly earnings.
  • Facebook, Inc. (NASDAQ: FB) rose 6% to $325.49 after the company reported upbeat results for its first quarter on Wednesday. The company reported 1.88 billion daily active users, up 8% year-over-year, as well as 2.85 billion monthly active users, up 10% year-over-year.
  • QUALCOMM Incorporated (NASDAQ: QCOM) rose 4% to $142.03 after the company reported better-than-expected Q2 results and issued strong Q3 EPS guidance.

Check out these big penny stock gainers and losers

Losers

  • Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares dipped 60.4% to $4.0250 after the company announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
  • Farmmi, Inc. (NASDAQ: FAMI) fell 56.3% to $0.3455 after the company priced its $42.0 million upsized underwritten public offering of ordinary shares.
  • Cara Therapeutics, Inc. (NASDAQ: CARA) fell 46% to $13.94 after the company announced mixed topline results from its KARE Phase 2 dose-ranging clinical trial of oral Korsuva for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients. The company said the study did not meet the primary endpoint of worst-itch NRS change from baseline at week 12 or secondary endpoint of 4-point responder analysis in the intent-to-treat patient population. However, the study achieved primary endpoint of worst-itch NRS change and secondary endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients, comprising 64% of ITT population.
  • Atomera Incorporated (NASDAQ: ATOM) fell 25.6% to $16.51 after the company reported Q1 earnings results.
  • Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) dipped 24.8% to $32.86. Brooklyn ImmunoTherapeutics acquired license for mRNA technology platform of Factor Bioscience Limited And Novellus Therapeutics Limited.
  • Impinj, Inc. (NASDAQ: PI) dropped 20.6% to $46.10 after reporting a decline in quarterly earnings.
  • Palisade Bio, Inc. (NASDAQ: PALI) fell 19.9% to $8.22.
  • Tiptree Inc. (NASDAQ: TIPT) fell 19.5% to $10.10 after the company reported it has decided to withdraw the registration statement relating to previously announced IPO by Fortegra due to ‘prevailing market conditions and the high value.’
  • Brightcove Inc. (NASDAQ: BCOV) dropped 19.3% to $15.69 after the company issued Q2 EPS and sales guidance below estimates.
  • FormFactor, Inc. (NASDAQ: FORM) fell 19% to $38.73 after the company reported worse-than-expected Q1 EPS results.
  • Selecta Biosciences, Inc. (NASDAQ: SELB) dipped 18.3% to $3.175. Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences.
  • Galectin Therapeutics Inc. (NASDAQ: GALT) shares fell 17% to $4.2350 after jumping over 22% on Wednesday. The company recently announced neurosurgeon Dr. Ben Carson, Sr. joined the team as a special consultant to accelerate and enhance development of the company's galectin-3 inhibitor, belapectin.
  • Vyant Bio, Inc. (NASDAQ: VYNT) fell 16.7% to $3.8750 after climbing 16% on Wednesday. Vyant Bio, Ordaōs Bio and Cellaria, recently announced collaboration to 'design and qualify biomarker-specific small protein therapeutics.'
  • MicroVision, Inc. (NASDAQ: MVIS) dipped 15.7% to $17.69.
  • 22nd Century Group, Inc. (NYSE: XXII) fell 15.6% to $4.7201.
  • Peabody Energy Corporation (NYSE: BTU) dropped 15.3% to $3.6301 following quarterly results.
  • Cohu, Inc. (NASDAQ: COHU) dipped 14.2% to $40.15 after reporting Q1 results.
  • Resolute Forest Products Inc. (NYSE: RFP) dropped 13.8% to $13.40 after reporting preliminary Q1 results.
  • Cree, Inc. (NASDAQ: CREE) fell 13.6% to $97.31 after the company issued Q4 EPS guidance below analyst estimates. JP Morgan also downgraded the stock from Neutral to Underweight.
  • Ribbon Communications Inc. (NASDAQ: RBBN) dipped 13.5% to $7.03 following weak quarterly sales.
  • Nemaura Medical Inc. (NASDAQ: NMRD) dipped 12.6% to $4.73.
  • eBay Inc. (NASDAQ: EBAY) fell 11% to $55.47. eBay reported upbeat Q1 earnings, but issued weak earnings guidance for the current quarter.
  • Teladoc Health, Inc. (NASDAQ: TDOC) fell 9.8% to $168.03 after reporting Q1 results.
  • Ford Motor Company (NYSE: F) fell 9.6% to $11.23 after the company reported Q1 earnings results.
  • Citrix Systems, Inc. (NASDAQ: CTXS) dropped 9.4% to $125.49 after the company reported worse-than-expected Q1 results.
  • Lyft, Inc. (NASDAQ: LYFT) fell 8.5% to $57.96 on reports the US Labor Secretary said most US gig workers should be classified as employees.
  • ServiceNow, Inc. (NYSE: NOW) fell 8% to $512.87 after the company reported Q1 earnings results.
  • Tenaris S.A. (NYSE: TS) fell 7.9% to $20.86 after the company reported Q1 results.
  • American Shared Hospital Services (NYSE: AMS) dropped 7.9% to $2.4498.
  • Hologic, Inc. (NASDAQ: HOLX) fell 7.3% to $67.11 after the company reported worse-than-expected Q2 results and issued weak Q3 guidance.
  • Ashford Hospitality Trust, Inc. (NYSE: AHT) fell 7.2% to $2.31 after surging around 32% on Wednesday.
 

Related Articles (ADS + ADVM)

View Comments and Join the Discussion!

Posted-In: Mid-Day MoversNews Penny Stocks Small Cap Intraday Update Markets Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com